Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Shares Issued: 2022-2025

Historic Shares Issued for Taysha Gene Therapies (TSHA) over the last 1 years, with Sep 2025 value amounting to $122,000.

  • Taysha Gene Therapies' Shares Issued rose 93.65% to $122,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $286,000, marking a year-over-year decrease of 51.44%. This contributed to the annual value of $89,000 for FY2024, which is 82.20% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported Shares Issued of $122,000 as of Q3 2025, which was up 62.67% from $75,000 recorded in Q1 2025.
  • In the past 5 years, Taysha Gene Therapies' Shares Issued ranged from a high of $450,000 in Q3 2023 and a low of -$11.4 million during Q4 2022.
  • Over the past 3 years, Taysha Gene Therapies' median Shares Issued value was $69,000 (recorded in 2024), while the average stood at $131,000.
  • Its Shares Issued has fluctuated over the past 5 years, first plummeted by 86.00% in 2024, then surged by 188.46% in 2025.
  • Quarterly analysis of 4 years shows Taysha Gene Therapies' Shares Issued stood at -$11.4 million in 2022, then crashed by 81.95% to $450,000 in 2023, then slumped by 86.00% to $63,000 in 2024, then spiked by 93.65% to $122,000 in 2025.
  • Its Shares Issued stands at $122,000 for Q3 2025, versus $75,000 for Q1 2025 and $63,000 for Q3 2024.